| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1749-6632.1992.TB51590.X |
| P8608 | Fatcat ID | release_s4kjmofpvbg7leixduvel6idde |
| P698 | PubMed publication ID | 1339240 |
| P50 | author | Jelena Gavrilovic | Q57160155 |
| P2093 | author name string | G. Murphy | |
| J. J. Reynolds | |||
| R. Ward | |||
| S. Atkinson | |||
| P2860 | cites work | Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. | Q38190315 |
| Cell-associated plasminogen activation: regulation and physiological functions | Q39607376 | ||
| Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation | Q40096626 | ||
| Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells | Q41514749 | ||
| Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). | Q41678253 | ||
| The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. | Q41770633 | ||
| Purification of recombinant human prostromelysin. Studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities | Q41856078 | ||
| Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes | Q41866734 | ||
| Comparison of human stromelysin and collagenase by cloning and sequence analysis | Q42128842 | ||
| Degradation of type I collagen films by mouse osteoblasts is stimulated by 1,25 dihydroxyvitamin D3 and inhibited by human recombinant TIMP (tissue inhibitor of metalloproteinases). | Q43568432 | ||
| Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties | Q28268723 | ||
| Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin) | Q28618144 | ||
| Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate | Q28618372 | ||
| Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members | Q34453431 | ||
| The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases | Q35301529 | ||
| In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. | Q36220034 | ||
| Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system | Q36223446 | ||
| Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro | Q36223450 | ||
| Isolation of a nonmitogenic angiogenesis factor from wound fluid | Q36326908 | ||
| Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation | Q37666731 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | connective tissue | Q25615 |
| plasminogen | Q107129060 | ||
| P304 | page(s) | 1-12 | |
| P577 | publication date | 1992-12-01 | |
| 1992-12-04 | |||
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | The role of plasminogen activators in the regulation of connective tissue metalloproteinases | |
| P478 | volume | 667 |
| Q39975026 | A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy |
| Q40771328 | A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion |
| Q28589602 | A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling |
| Q22011054 | A urokinase receptor-associated protein with specific collagen binding properties |
| Q47697374 | Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. |
| Q28373795 | Acetaldehyde increases the activity and gene expression of urokinase type plasminogen activator in a hepatic stellate cell line |
| Q33615455 | Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction |
| Q33749766 | Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. |
| Q28287089 | Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D |
| Q33876789 | Adhesion formation after laparoscopic surgery: what do we know about the role of the peritoneal environment? |
| Q48033529 | Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway |
| Q37495418 | Biomarkers of AAA progression. Part 1: extracellular matrix degeneration |
| Q38055477 | Cell surface remodeling by plasmin: a new function for an old enzyme |
| Q42004427 | Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases |
| Q71657591 | Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall |
| Q44508110 | Collagen type I, III and V differently modulate synthesis and activation of matrix metalloproteinases by cultured rabbit periosteal fibroblasts. |
| Q41481774 | Collagenase: a key enzyme in collagen turnover |
| Q74531892 | Complex alterations in gene expression occur in the knee ligaments of the skeletally mature multiparous rabbit during pregnancy |
| Q40598423 | Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors |
| Q33886514 | Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. |
| Q37949685 | Copper-induced hepatitis: the COMMD1 deficient dog as a translational animal model for human chronic hepatitis |
| Q78804814 | Decreased plasminogen activator inhibitor-1 secretion in hypoxic corneal epithelial cells is associated with increased urokinase plasminogen activator activity |
| Q42808161 | Dilong: role in peripheral nerve regeneration |
| Q38296528 | Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. |
| Q40874441 | Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells |
| Q35423717 | Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid |
| Q45712502 | Effect of malondialdehyde-acetaldehyde-protein adducts on the protein kinase C-dependent secretion of urokinase-type plasminogen activator in hepatic stellate cells |
| Q41185529 | Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty |
| Q54420587 | Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. |
| Q73025879 | Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta |
| Q91598075 | Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker |
| Q37386932 | Exacerbation of antigen-induced arthritis in urokinase-deficient mice |
| Q74098969 | Exposure to chronic hypoxia induces qualitative changes of collagen in the walls of peripheral pulmonary arteries |
| Q35751580 | Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion |
| Q52192855 | Expression of metalloproteases by cardiac myocytes and fibroblasts in vitro. |
| Q42469463 | Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma |
| Q47970481 | Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue |
| Q34143433 | Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. |
| Q77565069 | Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels |
| Q35869021 | High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis |
| Q53243561 | High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. |
| Q27681464 | Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM) |
| Q38259533 | Impact of proteolytic enzymes in colorectal cancer development and progression |
| Q73156216 | Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells |
| Q42259003 | Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. |
| Q72034087 | Interstitial Collagenase (MMP-1) Expression in Human Carotid Atherosclerosis |
| Q52051943 | Is collagen breakdown during periodontitis linked to inflammatory cells and expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gingival tissue? |
| Q35774094 | Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion |
| Q40860401 | Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases |
| Q40028510 | Matrix metalloproteinases in cerebral ischemia |
| Q34347211 | Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease |
| Q36429021 | Mechanisms of angiogenesis in gliomas |
| Q41754986 | Mechanisms of connective tissue matrix destruction in periodontitis |
| Q79249763 | Mice lacking tissue plasminogen activator and urokinase plasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush |
| Q94452435 | Muscarinic receptors modulate Nerve Growth Factor production in rat Schwann-like adipose-derived stem cells and in Schwann cells |
| Q36499227 | Oncolytic adenoviruses as antiglioma agents |
| Q40788383 | Overexpression of matrix metalloproteinase-2 mediates phenotypic transformation of lens epithelial cells |
| Q28543252 | PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like cultures |
| Q43053623 | Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints |
| Q73401976 | Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease |
| Q71778269 | Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein |
| Q71726352 | Plasminogen modulation of IL-1-stimulated degradation in bovine and human articular cartilage explants. The role of the endogenous inhibitors: PAI-1, alpha 2-antiplasmin, alpha 1-PI, alpha 2-macroglobulin and TIMP |
| Q33838161 | Proteases in gastrointestinal neoplastic diseases |
| Q40788261 | Protocatechuic Acid from Alpinia oxyphylla Induces Schwann Cell Migration via ERK1/2, JNK and p38 Activation |
| Q45878050 | RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. |
| Q35598320 | Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover |
| Q37363376 | Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator |
| Q48925891 | Reperfusion injury after stroke: neurovascular proteases and the blood-brain barrier |
| Q42455239 | Resveratrol down-regulates a glutamate-induced tissue plasminogen activator via Erk and AMPK/mTOR pathways in rat primary cortical neurons |
| Q35824305 | Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases |
| Q56834793 | Role of Urokinase in the Fibrogenic Response of the Lung to Mineral Particles |
| Q73632878 | Role of the plasminogen system in basal adhesion formation and carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice |
| Q42800879 | Schwann Cell Migration Induced by Earthworm Extract via Activation of PAs and MMP2/9 Mediated through ERK1/2 and p38. |
| Q38292946 | Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences |
| Q33678848 | Suppression of uPA and uPAR Attenuates Angiogenin Mediated Angiogenesis in Endothelial and Glioblastoma Cell Lines |
| Q57607629 | Surgical handling of saphenous vein grafts induces expression of matrix metalloproteinase 9 |
| Q33726930 | Synergy between a plasminogen cascade and MMP-9 in autoimmune disease |
| Q50466738 | The effect of suramin on the resorption of bovine nasal cartilage. |
| Q34249848 | The generation and characterization of mice expressing a plasmin-inactivating active site mutation |
| Q41391382 | Tissue inhibitors of metalloproteinases in liver fibrosis |
| Q31127095 | Tissue plasminogen activator in trabecular meshwork attenuates steroid induced outflow resistance in mice |
| Q35847359 | Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep |
| Q33887476 | Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration |
| Q33350682 | Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. |
| Q30439641 | Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion |
| Q52193484 | Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. |
| Q45884595 | Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation |
| Q34346433 | Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models. |
| Q36955412 | uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo |
| Q44732185 | uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. |
Search more.